Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Apr 25;3(2):e000521. doi: 10.1161/JAHA.113.000521

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2014 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell.

This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

PMC Copyright notice

Figure 3. — Treatment effect for the reduction of stroke or non‐CNS embolism in rivaroxaban and warfarin treated patients at a given cTTR threshold. The x‐axis shows the threshold value for cTTR and the y‐axis shows the HR for the time to stroke or non‐CNS embolism for rivaroxaban vs warfarin given a certain threshold cTTR. The y‐axis also shows the mean individual TTR in those centers that meet the threshold cTTR. There is instability in the estimate of the treatment effect at high cTTR thresholds due to smaller sample size, but no evidence that warfarin is superior to rivaroxaban in the prevention of stroke and systemic embolus at any cTTR threshold. CNS indicates central nervous system; cTTR, center time in therapeutic range; INR, international normalized ratio.